Why the Anteris (ASX:AVR) share price will be on watch today

The Anteris Technologies (ASX:AVR) share price will be on watch this morning following the release of the company's latest results.

| More on:
A boy with question mark on his forehead looking up as if watching an ASX share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Anteris Technologies Ltd (ASX: AVR) shares will be on watch this morning following the release of the company's preliminary results for the 2020 full year. At the closing bell yesterday, the Anteris share price finished the day down 3.8% at $5.00.

Let's take a look and see how the structural heart company performed for the period.

FY20 performance

The Anteris share price could be under pressure today after the company reported a disappointing end to its FY20 performance.

According to yesterday's late market release, Anteris advised it achieved a significant drop off across its key metrics.

For the period ending 31 December, total revenue fell to $7.1 million, a decline of 58% over the prior corresponding period. Most of the revenue generated came from the manufacturing of its CardioCel and VascuCel patches under the LeMaitre Vascular Inc. agreement. In addition, the company began winding down operations in the Infusion segment. COVID-19 had a minimal impact on Anteris due to the early implementation of its risk-management strategies.

Other income for the company totalled $4.8 million, which included $2.2 million in licencing income from 4C Medical Technologies. This was in relation to the transfer of the sterilisation method for use with Anteris' ADAPT tissue technology. The other monies consisted of research and development tax incentives and COVID-19 stimulus packages.

Investors will be eyeing off the Anteris share price in morning trade after the company reported earnings before interest, tax, depreciation and amortisation (EBITDA) sank to a loss of $13.7 million. This is in comparison to the EBITDA loss of $4.1 million recorded in the prior FY19 period.

Selling, general and administrative expenses stood at $22.1 million, an improvement from the $34.5 million in FY19. Initiated by management, cost-saving measures were attributed to lower employee, travel and conference costs. In addition, the prior period impairment of Admedus Vaccines, and favourable currency exchange movements helped support cost control.

Overall, the business recorded a net loss of $15.3 million, mostly due to investment in its 3D single-piece aortic DurAVR valve.

Anteris revealed a cash balance of $4.4 million for the end of December. It's worth noting that the company entered into a short-term facility for $1.2 million at an interest rate of 1.15% per month. The loan will be secured against the research and development refund.

The board declared that no dividend will be paid to shareholders.

About the Anteris share price

The Anteris share price is down over 30% since this time last year. Anteris shares reached a 52-week high of $9.18 in April, before plummeting down to a low of $3.01 in August.

Based on the current share price, Anteris has a market capitalisation of close to $33 million.

Should you invest $1,000 in Anteris Technologies Ltd right now?

Before you buy Anteris Technologies Ltd shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Anteris Technologies Ltd wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough trading day for ASX stocks this Monday.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in May

These stocks could be best buys this month according to the broker.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Oil worker using a smartphone in front of an oil rig.
Energy Shares

ASX 200 energy shares plunge on shock OPEC move

ASX 200 energy shares like Woodside and Santos are tumbling on Monday. Let’s find out why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why 4DMedical, Gold Road, Syrah, and Tyro shares are racing higher today

These shares are starting the week strongly. But why?

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

2 ASX gold stocks racing higher in Monday's sinking market

Investors are sending these ASX gold stocks flying higher on Monday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Brainchip, Helia Group, Reliance Worldwide, and Westpac shares are dropping today

These shares are starting the week in the red. But why?

Read more »

Man looking upwards contemplating which shares to buy
Broker Notes

CSL shares have climbed 10% since 11 April. Is it too late to buy?

What are analysts saying about this biotech giant after its recent rally? Let's find out.

Read more »